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Abstract
Background: The cellular retinol binding protein I gene (CRBP) is downregulated in a subset of
human breast cancers and in MMTV-Myc induced mouse mammary tumors. Functional studies
suggest that CRBP  downregulation contributes to breast tumor progression. What is the
mechanism underlying CRBP downregulation in cancer? Here we investigated the hypothesis that
CRBP is epigenetically silenced through DNA hypermethylation in human and mouse breast cancer.
Results: Bisulfite sequencing of CRBP in a panel of 6 human breast cancer cell lines demonstrated
that, as a rule, CRBP hypermethylation is closely and inversely related to CRBP expression and
identified one exception to this rule. Treatment with 5-azacytidine, a DNA methyltransferase
inhibitor, led to CRBP reexpression, supporting the hypothesis that CRBP hypermethylation is a
proximal cause of CRBP silencing. In some cells CRBP reexpression was potentiated by co-treatment
with retinoic acid, an inducer of CRBP, and trichostatin A, a histone deacetylase inhibitor. Southern
blot analysis of a small panel of human breast cancer specimens identified one case characterized
by extensive CRBP hypermethylation, in association with undetectable CRBP mRNA and protein.
Bisulfite sequencing of CRBP  in MMTV-Myc and MMTV-Neu/NT mammary tumor cell lines
extended the rule of CRBP hypermethylation and silencing (both seen in MMTV-Myc but not
MMTV-Neu/NT cells) from human to mouse breast cancer and suggested that CRBP
hypermethylation is an oncogene-specific event.
Conclusion: CRBP hypermethylation appears to be an evolutionarily conserved and principal
mechanism of CRBP silencing in breast cancer. Based on the analysis of transgenic mouse mammary
tumor cells, we hypothesize that CRBP silencing in human breast cancer may be associated with a
specific oncogenic signature.
Background
Retinol has been implicated in the regulation of adult epi-
thelial cell differentiation in addition to being essential
for normal embryonic development, vision and
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reproduction [1-3]. Most of the biological effects of reti-
nol are secondary to its metabolism to retinoic acid (RA)
and RA activation of members of the RA receptor (RAR)
and retinoid X receptor (RXR) family of ligand-dependent
transcription factors. As such, the study of RARs and RXRs
has gained widespread attention. However, a number of
other genes play fundamental roles in regulating RXR-RAR
function by regulating retinol and RA metabolism.
Among these genes is cellular retinol-binding protein I
(CRBP), which has been shown to be indispensable for
life when vitamin A levels in the diet are limiting. Thus,
CRBP null mice are unable to maintain adequate retinol
liver stores and survive only when dietary vitamin A is
abundant, a condition that is artificial and does not reflect
the dietary habits of mammals in the wild [4].
In addition to being expressed in stellate cells of the liver,
CRBP is expressed in many other organs and cell types
including epithelia [5-7]. Several observations, including
the finding that CRBP expression during mouse embryo-
genesis overlapped that of RARβ and RARγ, led to the sug-
gestion that the function of CRBP is to store and release
retinol where high levels of RA are developmentally
required [8]. mCRBP  expression is regulated by RA
through a RA response element located ~1 kb upstream of
the transcription start site, suggesting the existence of a
positive feedback mechanism for regulating retinoid
metabolism and action [9]. Glucocorticoids, cAMP, trans-
forming growth factor β and serum factors have also been
shown to impinge on CRBP expression [10-13]. The prox-
imal hCRBP promoter region has been cloned, the tran-
scription start site identified, and functional NF1 sites at
approximately -250 and +70 demonstrated [14,15] but
beyond these earlier studies there have been no functional
promoter analyses.
We have recently shown that CRBP expression is downreg-
ulated in a subset of human breast cancers [7]. In follow-
up studies of the potential significance of this finding, we
found that the downregulation of CRBP blocks the differ-
entiation and promotes the growth of SV40-transformed
breast epithelial cells ([16] and Farias et al., manuscript
submitted). The differentiation-promoting, growth-arrest-
ing effect of CRBP, witnessed in both human and mouse
mammary epithelial cells, was assigned to CRBP regula-
tion of retinol storage and RAR activation (Farias et al.,
manuscript submitted). These results suggested that CRBP
downregulation is a contributing cause rather than a con-
sequence of breast cancer and led us to investigate the
mechanism underlying CRBP downregulation. We report
here that CRBP is epigenetically silenced as a result of pro-
moter region hypermethylation in both human and
mouse breast cancer cells. Furthermore, we identify one
exception to this rule and provide data that suggests that
CRBP silencing is an oncogene-specific event at least in
the context of mouse mammary cancer. These results
extend those published by Esteller et al. while this work
was in progress [17].
Results
hCRBP expression in breast cancer cells varies widely
We first analyzed a panel of human breast cancer cell lines
for  CRBP  expression using a semi-quantitative RT-PCR
Southern blot protocol. CRBP  expression varied from
robust (MDA-MB-468), to weak (MCF-7), to very weak or
undetectable (ZR75-1 and MTSV1-7; Fig. 1A). Given that
CRBP downregulation occurs with an estimated frequency
of 24% in human breast cancer, i.e., it is not a universal
event, the identification of cell lines, such as MDA-MB-
468, in which CRBP was well expressed, should not be
surprising. We wondered whether the intermediate level
of CRBP expression in MCF-7 cells was a consequence of
clonal heterogeneity and tested this idea by random
clonal selection and analysis. In support of this notion, we
were able to isolate subclones that mirrored the extremes
of  CRBP  expression, with MCF-7 clone B resembling
MDA-MB-468 and MCF-7 clone A resembling ZR75-1
(Fig. 1B, compare with Fig. 1A). After densitometry and
normalization to a house keeping gene, we plotted the
results for all cell lines on a log scale (Figs. 2A and 3A).
hCRBP methylation, with one exception, is inversely 
proportional to hCRBP expression
On the basis of preliminary Southern blot analyses that
revealed no major hCRBP deletions or insertions in breast
cancer cells (unpublished data), and taking into account
the presence of a CpG island in the hCRBP  regulatory
region [14], we hypothesized that hCRBP downregulation
might be secondary to gene hypermethylation. This
hypothesis was tested by bisulfite sequencing of 26 CpG
dinucleotides within the hCRBP locus (promoter and 5'-
UTR region) in the cell lines whose CRBP expression we
had characterized (Fig. 1). We found that all 26 sites were
hypomethylated in MDA-MB-468 cells and 14 of the 26
sites were hypermethylated in ZR75-1 cells, providing the
first evidence of an inverse association between CRBP
methylation and expression (Fig. 2B). However, this
notion was challenged by the finding that the same CRBP
region was uniformly hypomethylated in MTSV1-7 cells
(Fig. 2B). The bisulfite sequencing analysis of CRBP in
MCF-7 parental cells and clones A and B proved very use-
ful in that it demonstrated a very tight inverse association
between  CRBP  methylation and expression. Thus, the
intermediate level of CRBP expression in parental MCF-7
cells was associated with a mixed pattern of CRBP methyl-
ation (of 17 amplicons sequenced, 6 showed uniform
hypermethylation and 10 showed uniform hypomethyla-
tion), and this mixed pattern resolved into uniform hyper
or hypomethylation in clones A and B, respectively (Fig.
3B). These results suggest that, as a rule, CRBP hypermeth-Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/13
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ylation is silencing, and that MTSV1-7 cells represent an
exception to this rule.
Treatment with a demethylating agent rescues hCRBP 
expression
CRBP  is a RA-inducible gene [9,18] and trichostatin A
(TSA), a histone deacetylase inhibitor, has been shown to
synergize with RAR induction of target gene transcription
[19]. Cells in culture vary widely in their sensitivity to
retinoids in the serum present in the culture medium; in
the case of MDA-MB-468 cells (hypomethylated CRBP),
there was robust CRBP expression in the absence of exog-
enous RA, whereas in the case of MCF-7 clone B cells (also
hypomethylated  CRBP) there was no CRBP  expression
unless exogenous RA was added and expression increased
further in presence of TSA (Fig. 4A). This difference may
relate to the fact that MDA-MB-468 cells are competent in
RA synthesis from serum retinol whereas MCF-7 cells are
not [20]. Based on the data for MCF-7 clone B cells (Fig.
4A), we predicted that treatment of MCF-7 clone A cells
(hypermethylated  CRBP) with 5-azacytidine (azaC), a
DNA methyltransferase inhibitor, would result in some
CRBP reexpression and that this effect would be potenti-
ated by the addition of RA and TSA. We further predicted
that in absence of azaC, RA and TSA would be ineffective.
The data confirmed these expectations (Fig. 4B), thus sup-
porting our hypothesis that hypermethylation is a proxi-
mal cause of CRBP silencing. In another cell line with
hypermethylated CRBP (ZR75-1), reexpression could also
be demonstrated to be critically dependent on azaC (Fig.
4A). Although we did not directly probe the effect of azaC
on CRBP methylation, we showed earlier that the same
protocol used here achieved partial demethylation of
another hypermethylated gene in MCF-7 cells [21]. The
work of Esteller et al. [17] suggest that our data for MCF-7
clone A is rather the exception than the rule in that azaC
alone is generally sufficient to achieve CRBP reexpression
when the gene is hypermethylated, suggesting that endog-
enous retinoids or other modulators of CRBP expression
(Introduction) can drive CRBP transcription upon azaC-
induced demethylation.
Extensive hCRBP hypermethylation in association with 
undetectable hCRBP in a human breast cancer specimen
Esteller et al. demonstrated by methylation-sensitive PCR
(MSP) that hCRBP is hypermethylated and silenced in a
subset of human breast cancers [17]. MSP is a highly sen-
sitive technique that will detect methylation of a gene of
interest even when only a small percentage of cells within
the tissue have methylated alleles [22]. We wished to
probe CRBP methylation using a less sensitive technique
to infer whether CRBP methylation was a rare event on a
per cell basis or, alternatively, was a tissue-wide event. For
this purpose we used a classical Southern blot analysis
approach [23] that relied on the use of methylation-sensi-
tive isoschizomers and knowledge of the specific CpG
sites that are methylated in human breast cancer cells
(Figs. 2B and 3B). To test the validity of this strategy, we
first applied it to MDA-MB-468 and ZR57-1 cells. South-
ern blotting correctly identified CRBP hypo and hyper-
methylation in MDA-MB-468 and ZR57-1 cells,
respectively (Fig. 5A). This strategy was then used to inves-
tigate CRBP methylation in a small panel of human breast
cancers (n = 10) and the results obtained for 2 cases are
hCRBP expression differs widely among human breast cancer  cell lines Figure 1
hCRBP expression differs widely among human 
breast cancer cell lines. A. RT-PCR Southern blot analy-
sis of CRBP expression in ZR75-1, MTSV1-7, MCF-7 and 
MDA-MB-468 cells. B. RT-PCR Southern blot analysis of 
CRBP expression in MCF-7 subclones and again MDA-MB-
468, to allow comparison with the cell lines studied in A. 
Cells were either untreated (MDA-MB-468) or treated with 
RA and TSA as further described in Fig. 4 (MCF-7 clone A 
and B cells). The data in Fig. 1 were used to generate Figs. 2A 
and 3A after densitometric analysis and normalization to 
autoradiographic exposure time (1 to 24 h) and GAPDH 
expression (loading control).
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hCRBP hypermethylation explains some but not all cases of hCRBP silencing Figure 2
hCRBP hypermethylation explains some but not all cases of hCRBP silencing. A. Relative levels of hCRBP expression 
determined by RT-PCR Southern analysis (see Fig. 1). The limit of detection is represented by a relative log value of 1.5 that 
corresponds to film background after 24 h exposure. Note that hCRBP expression in MDA-MB-468 cells is greater than that in 
ZR75-1 or MTSV1-7 cells by about 3 logs. B. hCRBP bisulfite sequencing results for the same cell lines as in A. Filled circles des-
ignate methylated and open circles designate unmethylated CpGs. Each row displays the methylation status of CpG sites across 
an individual amplicon; each "column" displays the methylation status of an individual CpG site across amplicons. The approxi-
mate position of each CpG site relative to the transcription start site is indicated in the abscissa.
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hCRBP methylation explains clonal variations in hCRBP expression Figure 3
hCRBP methylation explains clonal variations in hCRBP expression. A. Same as for Fig. 2A. Note that MCF-7 cells 
express hCRBP at a level that is intermediate to the extremes represented by MCF-7 clones A and B, which resemble in this 
regard ZR75-1 and MDA-MB-468 cells, respectively. B. hCRBP bisulfite sequencing results for the same cell lines as in A. Filled 
circles designate methylated and open circles designate unmethylated CpGs (see legend to Fig. 2B for futher details).
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shown in Fig. 5B. One breast cancer specimen (tumor B)
exhibited frank CRBP  hypermethylation in association
with low levels of CRBP mRNA, whereas tumor A did not
show evidence of CRBP methylation by Southern blotting
and this correlated with easily detectable CRBP mRNA lev-
els. Based on a densitometric evaluation of the yield of the
205 bp fragment, we estimate that >50% of the cells in
tumor B had at least one hypermethylated CRBP allele.
When viewed in the context of the other data presented
here and the work of Esteller et al. [17], this finding is of
interest because it suggests that in some breast cancers
there is clonal expansion of a cell population in which the
CRBP gene is hypermethylated. Fig. 5B also demonstrates
that there is good agreement between CRBP expression at
the mRNA and protein levels. Analysis of the remaining 8
human breast cancer specimens did not identify other
examples like tumor B in Fig. 5, either because of the small
sample size, the low sensitivity of Southern blotting, or
the low cellularity of the tumor specimen (data not
shown).
Myc but not Neu leads to mCRBP hypermethylation and 
silencing in mouse mammary epithelial cells
Morrison and Leder have shown that CRBP expression in
transgenic mouse mammary tumors is a function of the
initiating oncogene, with Myc-induced tumors lacking
and Neu-induced tumors displaying CRBP  expression
[24]. We hypothesized that this observation might be
Treatment with a demethylating agent rescues hCRBP expression in MCF-7 clone B and ZR75-1 cells Figure 4
Treatment with a demethylating agent rescues hCRBP expression in MCF-7 clone B and ZR75-1 cells. A. RT-
PCR Southern blot analysis of hCRBP expression in MDA-MB-468 and MCF-7 clone B cells treated as indicated, demonstrating 
different sensitivity to endogenous (serum) retinoids. RA, 1 µM all-trans RA; TSA, 100 nM trichostatin A (24 h treatment). B. 
RT-PCR Southern analysis of hCRBP expression in MCF-7 clone A and ZR75-1 cells treated as indicated, demonstrating that a 
demethylating agent is required for CRBP reexpression. AzaC, 5 µM 5-azacytidine (72 h pretreatment, 96 h total); RA and TSA 
as above (present during last 24 h).
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In some human breast cancers, hCRBP hypermethylation is widespread Figure 5
In some human breast cancers, hCRBP hypermethylation is widespread. A. Sketch outlining the Southern blot strat-
egy used to evaluate hCRBP methylation in human breast cancer specimens. The strategy was tested in MDA-MB-468 and 
ZR75-1 cells whose hCRBP methylation status was known beforehand. B, BH and BM stand for, respectively, Bsu36I digestion 
alone, Bsu36I digestion followed by Hpall digestion, and Bsu36I digestion followed by MspI digestion (MspI is the methylation-
insensitive isoschizomer of Hpall). In agreement with the bisulfite sequencing data, Southern blotting revealed hCRBP under-
methylation in MDA-MB-468 and hypermethylation in MCF-7 clone A cells (note loss of the large Bsu36I fragment after BH 
digestion of MDA-MB-468 genomic DNA and retention of this fragment in the case of MCF-7 clone A). A hCRBP restriction 
fragment length polymorphism (an extra Bsu36I site within the 205 bp fragment) accounts for the displaced band migration pat-
tern in MDA-MB-468 cells. B. Southern, RT-PCR and Western blotting results for 2 human breast cancer specimens. The yield 
of the 205 bp product was decreased by >50% after BH digestion relative to BM digestion. We infer from this that >50% of the 
cells in the tumor displayed hCRBP hypermethylation. The protein blot was post-stained with Ponceau S and a major band used 
as loading control.
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explained by Myc but not Neu promotion of CRBP hyper-
methylation. To test this, we obtained two mammary
tumor cell lines established from Myc and two others
established from Neu-induced tumors [25] and, as a first
step, confirmed that CRBP was expressed in the latter but
not the former cell lines (Fig. 6A). We then analyzed CRBP
methylation in the same cell lines. As predicted by our
hypothesis, bisulfite sequencing of CpG dinucleotides
within the mCRBP promoter and 5'-UTR region revealed
extensive to moderate CRBP hypermethylation in MMTV-
Myc as opposed to virtually no methylation in MMTV-
Neu mammary tumor cells (Fig. 6B). As shown in Fig. 6C,
treatment with azaC rescued CRBP expression in MMTV-
Myc (16MB9a) cells. Thus, CRBP hypermethylation and
silencing appears to represent an evolutionarily conserved
event in mammary carcinogenesis. The data in Fig. 6 sets
the stage for additional work investigating whether CRBP
hypermethylation in human breast cancer can be associ-
ated with a specific oncogenic signature.
Discussion
Our data extend the work of Esteller et al. [17] in several
respects. First, it provides an analysis of the pattern of CpG
methylation across the CRBP promoter region. One inter-
esting feature revealed by the bisulfite sequencing of CRBP
in ZR75-1 and MCF-7 clone A cells, both of which express
virtually no CRBP, is that 2 alternative methylation pat-
terns are equally suppressive. Thus, in ZR75-1 cells, CRBP
methylation showed intra-allelic variegation, with alter-
nating methylated and non-methylated CpG sites (Fig.
2B). Contrast this with the uniform methylation of all
CpG sites in MCF-7 clone A cells (Fig. 3B). As shown in
Fig. 4, both of these patterns contributed to CRBP down-
regulation, suggesting that uniform methylation is not
required for silencing, which is consistent with the dem-
onstrated ability of MeCP2 to bind single methylated CpG
sites [26]. CRBP  methylation in MMTV-Myc mammary
tumor cells defined yet another methylation pattern char-
acterized by both intra- and inter-allelic variegation and
different degrees of methylation penetrance (Fig. 6B). The
conditions that lead to the establishment of these variant
methylation patterns in the first place are not known.
Second, our data identified the MTSV1-7 cell line as an
exception to the rule that CRBP silencing is associated
with CRBP hypermethylation. The mechanism responsi-
ble for CRBP silencing in MTSV1-7 cells remains to be
identified but the ease with which CRBP can be ectopi-
cally expressed in these cells from a heterologous pro-
moter points to a defect in transcriptional initiation rather
than a subsequent event [16]. In view of the association
between MMTV-Myc expression and mCRBP  silencing
(Fig. 6), we hypothesize that c-myc overexpression may
underly hCRBP silencing in MTSV1-7 cells. This possibil-
ity is supported by our finding that c-myc protein is easily
detected in MTSV1-7 cells by direct Western whereas it is
normally present in trace levels (Farias and Mira-y-Lopez,
unpublished data). c-myc protein levels in MTSV1-7 cells
may be elevated either as a result of their long-term
passage in vitro [27] and/or as a result of their transduc-
tion with the SV40 small t antigen [28], which was
recently shown to stabilize c-myc [29]. That possibility is
further supported by the finding that immortalized
mouse mammary epithelial cells lose endogenous mCRBP
expression over long term in vitro passage (Farias and
Mira-y-Lopez, unpublished data). On the other hand, the
fact that MMTV-Myc is associated with mCRBP  hyper-
methylation (Fig. 6) but hCRBP was not hypermethylated
mCRBP hypermethylation and silencing is an oncogene-spe- cific event Figure 6
mCRBP hypermethylation and silencing is an onco-
gene-specific event. A. Northern blot analysis. B. mCRBP 
bisulfite sequencing results for the cell lines tested in A. Each 
row corresponds to one sequenced amplicon. Filled circles 
designate methylated and open circles designate unmethyl-
ated CpGs (ee legend to Fig. 2B for futher details). C. RT-
PCR demonstrating effect of azaC treatment (as in Fig. 4) on 
mCRBP expression in 16MB9a cells.
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in MTSV1-7 cells (Fig. 2B) argues against our idea that c-
myc overexpression underlies CRBP silencing in MTSV1-7
cells. However, hypermethylation has been suggested to
represent a mechanism for the maintenance not the initial
induction of transcriptional silencing [30]. Therefore, it is
conceivable that the hCRBP  locus in MTSV1-7 cells is
repressed in a c-myc-dependent manner and is susceptible
to but has not yet undergone hypermethylation.
Third, based on a small sample of 10 human breast cancer
specimens, we succeeded in identifying one instance of
widespread CRBP hypermethylation and silencing. Thus,
hypermethylation was easily detected in total tumor DNA
using a low sensitivity technique (Southern blotting) and
this correlated with the lack of any detectable CRBP
mRNA and protein in total tumor RNA and tumor lysates,
respectively. Although only a single such tumor was iden-
tified, it seems reasonable to extrapolate, based on the
strength of the combined evidence ([17] and this report),
that a small subset of human breast cancers are character-
ized by pervasive CRBP methylation.
Fourth, we have found that mCRBP methylation is associ-
ated with Myc but not Neu-induced mammary tumors,
suggesting that mCRBP silencing may be a requirement for
MMTV-Myc tumorigenesis. We plan to test this hypothesis
by monitoring CRBP expression and methylation by in
situ hybridization and MSP, respectively, over the period
of time during which premalignant changes accumulate
in MMTV-Myc mammary tissue. We expect to find that
CRBP  downregulation precedes or coincides with the
appearance of preneoplasia. We further expect that
ectopic CRBP will prevent or delay the onset of mammary
tumorigenesis. One theoretical argument against our
hypothesis is that MMTV-Myc may transform a
subpopulation of cells that do not express CRBP to begin
with. We find this unlikely because CRBP mRNA is
uniformly expressed in both layers of human breast ducts,
i.e., the epithelium itself and the underlying myoepithe-
lium [7]. Interestingly, MMTV-Myc tumors were recently
identified as having both epithelial and myoepithelial
components [31], suggesting that MMTV-Myc transforms
a pluripotent cell population. For the reason just stated
above, we hypothesize that this population expresses
CRBP.
Finally, our study of CRBP methylation in mouse mam-
mary tumor cell lines derived from Myc and Neu-induced
tumors provides a hypothetical explanation for why CRBP
hypermethylation is characteristic of only a subset of
human breast cancers. It should be noted that CRBP is not
unique in this regard, i.e., several other genes shown to be
epigenetically silenced in breast cancer are silenced in a
subset of, not all breast cancers [32]. The data in Fig. 6 sug-
gests that subset-specific CRBP  silencing might be
explained by the nature of the initiating oncogenic event.
Specifically, we propose that most human breast cancers
in which c-myc is amplified and/or overexpressed might
be characterized by CRBP  hypermethylation and, con-
versely, most breast cancers with c-neu amplification and/
or overexpression might be characterized by CRBP
hypomethylation. Interestingly, the incidence of c-myc
amplification and CRBP hypermethylation in breast can-
cer have both been estimated at 16% [17,33]. If further
work were to validate this notion, then it would be of
interest to understand how c-myc overexpression leads to
CRBP silencing and how c-neu bypasses the anti-tumor
function of CRBP. The finding of other defects in retinol
and RA metabolism in breast cancer as well as alterations
in RAR isoform expression suggest that several bypassing
mechanisms may exist [34-37].
Conclusions
We conclude that: (i) CRBP hypermethylation is, as a rule,
a proximal cause of CRBP silencing in a subset of human
and mouse breast cancers; (ii) exceptions to this rule may
exist in some human breast cancers, as indicated by our
results for the MTSV1-7 cell line, in which CRBP  is
silenced despite being hypomethylated; (iii) the intra-
allelic pattern of CRBP hypermethylation may vary and
tumors may consist of mixtures of cells with hyper and
hypomethylated CRBP, but in at least some cases most
tumor cells (>50%) display CRBP hypermethylation; (iv)
at least in the context of mouse mammary cancer, CRBP
hypermethylation appears to be an oncogene-specific
event. The significance of these findings should be viewed
against the background of our functional analyses of
CRBP, which suggest that CRBP silencing is a contributing
cause rather than a consequence of breast carcinogenesis
[16].
Methods
Cells and reagents
Human breast cancer cell lines, with the exception of
MTSV1-7 cells [16,28], were obtained from the American
Type Culture Collection (Rockville, MD) and grown as
recommended. 16MB9a and M1011 (MMTV-Myc) and
SMF and NAF (MMTV-Neu/NT) mammary tumor cells
were cultured as described [24]. Gel purified primers were
obtained from Genelink (Hawthorne, NY). RA, TSA and
azaC were obtained from Sigma (St.Louis, MO). Sodium
metabisulfite was obtained from BDH, England.
RNA analyses
For RT-PCR, 2 µg total RNA (Purescript kit, Gentra, Min-
neapolis, MN) were reverse transcribed using the Super-
script Preamplification System (Gibco BRL Life
Technologies, Grand Island, NY). This RNA input was
chosen after preliminary experiments demonstrated a
dose-dependent increase in CRBP RT-PCR product withinMolecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/13
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the range of 0.5 to 4 µg total RNA. The PCR mixture con-
sisted of 10X PCR Buffer, 1 mM MgCl2, 200 µM dNTPs,
0.4 µM each primer, 10% cDNA, and 5U of Taq (Promega,
Madison, WI) in a total volume of 50 µl. hCRBP cDNA
(320 bp) was amplified with sense primer TTGT-
GGCCAAACTGGCTCCA and antisense primer ACACT-
GGAGCTTGTCTCCGT and the following cycling
parameters: 94 C for 5 min; 26 cycles of 94 C for 1 min,
48 C for 1 min, 72 C for 1 min; 72 C for 5 min. 18S rRNA
(489 bp) was amplified using the same protocol as above
except that 5% cDNA, a 3:7 mix of primers:competimers
(0.4 µM total), and an annealing temperature of 57°C
were used (18S rRNA primers and competimers were from
Ambion, Austin, TX). GAPDH RT-PCR was performed as
described [38]. The PCR products were separated on 1%
agarose, stained with ethidium bromide (18S rRNA) or
blotted overnight and probed with full length CRBP
cDNA or a commercial GAPDH cDNA fragment
(Ambion). Northern blot analyses were performed using
standard methods and a full length CRBP cDNA probe as
described earlier [7].
Bisulfite sequencing
Genomic DNA was isolated using the Puregene kit (Gen-
tra Minneapolis, MN) and digested with XbaI. The
bisulfite method established by Frommer et al. [39,40]
was carried out on 5 µg genomic DNA digest with the fol-
lowing modifications. Digested DNA was denatured with
0.5 M NaOH at 75 C for 15 min, followed by deamination
with freshly prepared 4.0 M, pH 5.0 sodium metabisulfite
and incubated at 55 C for 8 hours in a total volume of 1.2
ml under mineral oil. The bisulfite-treated DNA was then
desalted using the Wizard DNA clean-up system
(Promega), desulfonated with 0.3 M NaOH at 37 C for 15
min, neutralized with 0.1 volume of 3 M NH4AC and eth-
anol precipitated with 2 volumes of cold ethanol. The
pellet was resuspended in 50 µ1 of sterile H2O. A 780 bp
hCRBP fragment was amplified using 2 rounds of fully-
nested PCR, which in our experience was required to yield
reproducible results. First round PCR was carried out in a
50 µl reaction mixture of 10X PCR buffer, 1.2 mM MgCl2,
160 µM dNTPs, 0.4 µM each primer, 10 µl of bisulfite-
treated DNA, and 5 U of Taq (Promega). The nested PCR
reactions (rounds 2 and 3) were carried out in the same
way using 5% of the product obtained in the preceding
round as template. The primers used were as follows: 1st
round PCR, GTTGAATTTTTTAGTTTTTTTGATTTTAGT
(sense) and ACACCAAAAAATTAACAAAAAAACT
(antisense); 2nd round, AGGTTTTAGATAAAGGTTTG-
TAAGTGG (sense) and TCCCAAAATAACAAAAC-
CCCAAAAA (antisense); 3rd round,
GTTTTTTAATTTTTGAGTGGTTGT (sense) and ATCTA-
CAACCTAAAAACTACCCTAAAA (antisense). Cycling
parameters were: 94 C for 5 min; 40 (round 1) or 20 cycles
(rounds 2 and 3) of 94 C for 1 min, 45 C (rounds 1 and
3) or 50 C (round 2) for 1 min, 72 C for 1 min; 72 C for
5 min. The amplified PCR product was gel purified, sub-
cloned into the TA cloning vector (Invitrogen, Faraday,
CA), transformed into TOPO kit cells (Invitrogen) using a
blue-white colony X-gal selection, and individual clones
submitted for sequencing. mCRBP bisulfite sequencing
was performed essentially as described above for hCRBP
but using semi-nested PCR and the following primers and
conditions: 1st  round, TGAAGGATTTTTAAGGGAAG-
TAAGGAG (sense) and AAATTCTCATTACTCAACATCT-
TCCAATAC (antisense), 40 cycles, annealing at 52 C; 2nd
round, ATCCACAAACATTTTTAAAACAAACTA (sense)
and same antisense primer as above, 42 cycles, annealing
at 46 C.
Southern blot analysis
Human breast carcinoma specimens that had been flash
frozen within 1 h of surgery were obtained through the
Cooperative Human Tissue Network http://
www.chtn.ims.nci.nih.gov under Institutional Review
Board approval. All specimens were diagnosed as invasive
breast carcinoma, with or without a carcinoma in situ
component, except for one specimen which was an ade-
noid cystic breast carcinoma (not shown in Fig. 5).
Approximately 200 mg of tissue were pulverized under
liquid nitrogen and RNA and DNA isolated using Qia-
gen's RNA/DNA kit according to manufacturer's instruc-
tions (Qiagen, Valencia, CA). Tumor DNA (45 µg) was
digested with Bsu36I, ethanol precipitated, and divided
into 3 parts that were either not digested further, digested
with HpaII, or digested with MsPI (restriction enzymes
were from New England Biolabs, Beverly, MA). After eth-
anol precipitation, Southern blots were prepared and
hybridized to a 205 bp hCRBP probe amplified from a
cloned  hCRBP  genomic fragment using CCGGTCTC-
CTCTTCCTTTGTAGGGG (sense) and GGGACAG-
GGGGCTCTGCGGGG (antisense) primers.
Immunoblot analysis
A small amount of pulverized tissue was homogenized in
10 mM Tris.Cl pH 7.4, 1 mM EDTA, 7 µM beta-mercap-
toethanol, the homogenate was centrifuged at 10,000 × g
for 10 min, and the supernatant centrifuged further at
100,000 × g for 30 min to yield cytosol. Protein concen-
tration was analyzed using the method of Bradford [41]
with Bio-Rad reagents (Bio-Rad, Hercules, CA) and 50 µg
protein were electrophoresed per lane in a 15% sodium
dodecyl sulfate-polyacrylamide gel. After blotting, CRBP
protein was visualized by reaction with anti-CRBP anti-
body followed by secondary antibody and enhanced
chemiluminescence detection. The anti-CRBP antibody
was raised in rabbits against a keyhole limpet hemocy-
anin-conjugated CRBP-specific peptide [42] and was char-
acterized elsewhere [16].Molecular Cancer 2004, 3 http://www.molecular-cancer.com/content/3/1/13
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List of abbreviations
CRBP cellular retinol binding protein type I
MMTV mouse mammary tumor virus
RA retinoic acid
RAR RA receptor
RXR retinoid x receptor
RT-PCR reverse transcription-coupled polymerase chain
reaction
ER estrogen receptor
TSA trichostatin A
azaC 5-azacytidine
MSP methylation-sensitive PCR
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